Anti-inflammtory therapeutic - Qubit Pharmaceuticals
Latest Information Update: 31 Mar 2025
At a glance
- Originator Qubit Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Interleukin 4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 12 Mar 2025 Anti-inflammtory therapeutic - Qubit Pharmaceuticals is available for licensing as of 12 Mar 2025. Qubit Pharmaceuticals pipeline, March 2025
- 12 Mar 2025 Early research in Inflammation in France (unspecified route) before March 2025 (Qubit Pharmaceuticals pipeline, March 2025)